Your browser is no longer supported. Please, upgrade your browser.
Settings
AGIO Agios Pharmaceuticals, Inc. daily Stock Chart
AGIO [NASD]
Agios Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-6.03 Insider Own0.30% Shs Outstand58.78M Perf Week1.46%
Market Cap3.36B Forward P/E- EPS next Y-6.34 Insider Trans-21.45% Shs Float50.85M Perf Month-13.30%
Income-346.00M PEG- EPS next Q-1.75 Inst Own- Short Float16.20% Perf Quarter10.07%
Sales94.40M P/S35.59 EPS this Y10.80% Inst Trans0.59% Short Ratio19.77 Perf Half Y-9.00%
Book/sh11.81 P/B4.84 EPS next Y9.20% ROA-36.20% Target Price86.00 Perf Year-31.99%
Cash/sh9.96 P/C5.74 EPS next 5Y- ROE-44.10% 52W Range41.63 - 99.82 Perf YTD23.96%
Dividend- P/FCF- EPS past 5Y-16.40% ROI- 52W High-42.74% Beta2.33
Dividend %- Quick Ratio6.60 Sales past 5Y29.90% Gross Margin98.50% 52W Low37.30% ATR2.50
Employees482 Current Ratio6.60 Sales Q/Q206.10% Oper. Margin- RSI (14)38.21 Volatility4.16% 3.99%
OptionableYes Debt/Eq0.00 EPS Q/Q12.80% Profit Margin- Rel Volume0.60 Prev Close56.83
ShortableYes LT Debt/Eq0.00 EarningsMay 16 BMO Payout- Avg Volume416.60K Price57.16
Recom2.00 SMA20-8.62% SMA50-8.61% SMA200-13.56% Volume251,938 Change0.58%
Feb-15-19Upgrade SVB Leerink Mkt Perform → Outperform $80
Sep-25-18Initiated Leerink Partners Mkt Perform
May-23-18Initiated Citigroup Buy $117
Apr-11-18Reiterated Credit Suisse Outperform $80 → $95
Feb-15-18Reiterated SunTrust Buy $80 → $101
Feb-15-18Reiterated Needham Buy $72 → $86
Sep-15-17Initiated RBC Capital Mkts Outperform $78
Aug-10-17Reiterated Needham Buy $54 → $72
Aug-08-17Reiterated SunTrust Buy $68 → $80
Aug-02-17Upgrade Leerink Partners Mkt Perform → Outperform $80
Jun-26-17Downgrade Janney Buy → Neutral
Jan-17-17Upgrade Oppenheimer Perform → Outperform
Oct-24-16Initiated Needham Buy $60
Jun-13-16Upgrade JP Morgan Neutral → Overweight
May-18-16Reiterated SunTrust Buy $57 → $65
May-18-16Reiterated Sun Trust Rbsn Humphrey Buy $57 → $65
Mar-30-16Initiated Sun Trust Rbsn Humphrey Buy $57
Jan-21-16Initiated Credit Suisse Outperform
Dec-07-15Downgrade Leerink Partners Outperform → Mkt Perform
Nov-09-15Reiterated ROTH Capital Neutral $114 → $75
Apr-25-19 04:00PM  Agios to Webcast Conference Call of First Quarter 2019 Financial Results on May 2, 2019 GlobeNewswire
Apr-11-19 03:27PM  What Are Analysts Saying About Agios Pharmaceuticals, Inc.'s (NASDAQ:AGIO) Earnings Outlook? Simply Wall St.
Apr-02-19 04:00PM  Agios Announces New Commercial Leadership Structure GlobeNewswire
10:09AM  AVEO Reports Positive Results on Leukemia Drug, Shares Up Zacks
Mar-27-19 10:48AM  Agios (AGIO) Surges More Than 40% Year to Date: Here's Why Zacks
10:45AM  Agios Gains Breakthrough Therapy Status for Tibsovo Combo Zacks
Mar-26-19 04:00PM  Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) with an IDH1 Mutation in Adult Patients Ineligible for Intensive Chemotherapy GlobeNewswire +5.07%
Mar-16-19 09:30AM  Why Is Agios Pharmaceuticals (AGIO) Up 13.2% Since Last Earnings Report? Zacks
Mar-06-19 02:01PM  All You Need To Know About Agios Pharmaceuticals, Inc.s (NASDAQ:AGIO) Financial Health Simply Wall St. -6.11%
Mar-04-19 07:00AM  Agios to Present at the Cowen 39th Annual Health Care Conference on Monday, March 11, 2019 GlobeNewswire
Feb-25-19 07:00AM  Agios Reports Updated Data from Phase 1 Study of Ivosidenib in Combination with Azacitidine Demonstrating Deep and Durable Responses in Newly Diagnosed IDH1 Mutant Acute Myeloid Leukemia (AML) Patients GlobeNewswire +5.93%
Feb-22-19 07:25AM  Analysis: Positioning to Benefit within Quest Diagnostics, Autodesk, Agios Pharmaceuticals, AMN Healthcare Services, Vistra Energy, and Helen of Troy Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Feb-21-19 09:34AM  Agios' Tibsovo Gets FDA Priority Review in First-Line Cancer Zacks
07:00AM  Agios to Present at the Leerink Global Healthcare Conference on Thursday, February 28, 2019 GlobeNewswire
Feb-20-19 03:43PM  Edited Transcript of AGIO earnings conference call or presentation 14-Feb-19 1:00pm GMT Thomson Reuters StreetEvents
07:00AM  Agios Announces FDA Acceptance of Supplemental New Drug Application for TIBSOVO® (ivosidenib) for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy GlobeNewswire
Feb-15-19 02:25PM  Agios (AGIO) Q4 Earnings Beat, Tibsovo Sales Push Up Stock Zacks
Feb-14-19 12:01PM  Agios Pharmaceuticals Inc (AGIO) Q4 2018 Earnings Conference Call Transcript Motley Fool +6.27%
09:10AM  Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates Zacks
08:10AM  Agios Pharmaceuticals: 4Q Earnings Snapshot Associated Press
07:00AM  Agios Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Feb-11-19 12:09PM  Agios ex-CEO joins GV as life sciences investment team's co-head American City Business Journals
Feb-07-19 10:31AM  Agios Pharmaceuticals (AGIO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Jan-29-19 01:52PM  Have Insiders Been Selling Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares? Simply Wall St.
Jan-10-19 12:07PM  5 Biotech Stocks That Could Face M&A Next! InvestorPlace
Jan-07-19 07:00AM  Agios Highlights Key 2019 Initiatives to Broaden Potential for Cancer and Rare Genetic Disease Programs to Build Long-Term Value GlobeNewswire +8.70%
Dec-28-18 07:00AM  Agios to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 GlobeNewswire
Dec-14-18 12:03PM  Our Take On Agios Pharmaceuticals, Inc.s (NASDAQ:AGIO) CEO Salary Simply Wall St.
Dec-13-18 07:20AM  Market Trends Toward New Normal in DXC Technology, Patterson Companies, Lumentum, DSW, Agios Pharmaceuticals, and Six Flags Entertainment Corporation New Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
03:20AM  Hedge Funds Are Selling Agios Pharmaceuticals Inc (AGIO) Insider Monkey
Dec-12-18 07:00AM  Today's Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Agios Pharmaceuticals ACCESSWIRE
Dec-08-18 05:36PM  Could These Be the Next 2 Biotech Buyouts? Motley Fool
Dec-07-18 07:00AM  Today's Research Reports on Trending Tickers: Amarin Corporation and Agios Pharmaceuticals ACCESSWIRE -5.37%
Dec-03-18 10:30AM  Agios Presents Updated Data from the Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1 Mutant Positive Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible for Standard Treatment and Myelodysplastic Syndrome (MDS) GlobeNewswire -13.66%
10:15AM  Agios Announces Updated Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Standard Induction and Consolidation Chemotherapy in Newly Diagnosed AML Patients With an IDH Mutation GlobeNewswire
07:00AM  Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Exelixis ACCESSWIRE
Nov-26-18 07:05AM  Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Amarin Corporation ACCESSWIRE
Nov-19-18 05:00AM  Edited Transcript of AGIO earnings conference call or presentation 1-Nov-18 12:00pm GMT Thomson Reuters StreetEvents
Nov-16-18 07:00AM  Agios Presents Updated Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma GlobeNewswire
Nov-14-18 06:55AM  Today's Research Reports on Trending Tickers: Exelixis and Agios Pharmaceuticals ACCESSWIRE
Nov-08-18 08:00AM  New Research Coverage Highlights John B. Sanfilippo & Son, Axcelis Technologies, Cogent Communications, Star Bulk Carriers, Agios Pharmaceuticals, and MDC Partners Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
06:00AM  3 Biotech Stocks Poised for Big Rebounds Investopedia
Nov-02-18 01:01PM  Agios (AGIO) Q3 Earnings Beat, Tibsovo Sales Drive Stock Zacks
Nov-01-18 10:41AM  Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Tops Revenue Estimates Zacks +8.64%
09:20AM  Agios to Present Updated Clinical Data at the 2018 ASH Annual Meeting GlobeNewswire
08:22AM  Agios Pharmaceuticals: 3Q Earnings Snapshot Associated Press
08:00AM  Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Incyte ACCESSWIRE
07:00AM  Agios Reports Third Quarter 2018 Financial Results GlobeNewswire
Oct-19-18 11:44AM  Agios Rides on Tibsovo Approval Amid Reliance on Celgene Zacks
Oct-18-18 07:00AM  Agios to Webcast Conference Call of Third Quarter 2018 Financial Results on November 1, 2018 GlobeNewswire -6.62%
Oct-04-18 07:50AM  New Research Coverage Highlights Camden Property Trust, Agios Pharmaceuticals, Crane, BorgWarner, Cognizant Technology Solutions, and Liberty Broadband Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Oct-01-18 06:35AM  After auspicious run at Agios, biotech exec David Schenkein mulls future American City Business Journals
Sep-19-18 09:37AM  Is Agios Pharmaceuticals Inc (NASDAQ:AGIO) Worth US$71.67 Based On Intrinsic Value? Simply Wall St.
Sep-06-18 08:00AM  Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Ultragenyx Pharmaceutical ACCESSWIRE
Sep-05-18 10:21AM  Agios (AGIO) Assigns Ex-Celgene Executive to CEO Position Zacks
08:28AM  The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results Benzinga
Sep-04-18 06:33PM  Agios names former Celgene executive Jacqualyn Fouse as next CEO Reuters
06:12PM  Agios names former Celgene executive Jacqualyn Fouse as next CEO Reuters
05:57PM  Agios Announces Chief Executive Officer Succession Plan GlobeNewswire
04:53PM  [$$] Agios Pharmaceuticals Plans to Pump Cash Into R&D The Wall Street Journal
Aug-28-18 07:00AM  Agios to Present at the Citi 13th Annual Biotech Conference Wednesday, September 5, 2018 GlobeNewswire
Aug-17-18 11:49PM  Edited Transcript of AGIO earnings conference call or presentation 2-Aug-18 12:00pm GMT Thomson Reuters StreetEvents
Aug-13-18 09:30AM  Opening Bell, August 13, 2018 CNBC Videos
Aug-03-18 11:55AM  Agios (AGIO) Q2 Loss Narrows, Revenues Surpass Estimates Zacks
Aug-02-18 09:25AM  Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates Zacks -7.29%
08:47AM  Agios (AGIO) Q2 Loss Narrows, Revenue Beat Estimates Zacks
08:19AM  Agios Pharmaceuticals: 2Q Earnings Snapshot Associated Press
07:00AM  Agios Reports Second Quarter 2018 Financial Results GlobeNewswire
06:00AM  Agios Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Jul-30-18 11:25AM  What's in the Cards for Agios (AGIO) Stock in Q2 Earnings? Zacks
Jul-25-18 08:12AM  Biotech Stock Roundup: Biogen Gains on Q2 Results, Agios Gets FDA Nod For Leukemia Drug Zacks
Jul-23-18 11:26AM  Agios (AGIO) Secures FDA Approval for Leukemia Drug Tibsovo Zacks
07:00AM  Agios to Webcast Conference Call of Second Quarter 2018 Financial Results on August 2, 2018 GlobeNewswire
Jul-20-18 02:46PM  Cambridge's Agios wins FDA approval for second cancer drug American City Business Journals
10:59AM  FDA approves Agios Pharmaceuticals leukemia drug Reuters
10:45AM  FDA Grants Approval of TIBSOVO®, the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation GlobeNewswire
Jun-29-18 07:50AM  Analysis: Positioning to Benefit within Biglari, Trustmark, Allscripts Healthcare Solutions, Agios Pharmaceuticals, Roadrunner Transportation, and OSI Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jun-27-18 11:32AM  Agios Out-Licenses China Rights to Leukemia Drug Tibsovo Zacks
Jun-26-18 08:16AM  BRIEF-Agios And CStone Pharmaceuticals Announce Exclusive Collaboration And License Agreement To Develop And Commercialize Ivosidenib In Greater China Reuters -5.30%
08:00AM  Agios and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Ivosidenib in Greater China GlobeNewswire
Jun-21-18 08:39AM  Benzinga's Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street Benzinga
Jun-20-18 03:54AM  Agios (AGIO) Initiates Phase III Study on PK Deficiency Drug Zacks
Jun-18-18 07:00AM  Agios Announces Initiation of Global Phase 3 Trial (ACTIVATE) of AG-348 in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused GlobeNewswire
Jun-05-18 12:04PM  Agios Pharmaceuticals, Inc.Stock Is an Analyst Darling for Good Reason InvestorPlace
Jun-04-18 09:00AM  New Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients GlobeNewswire
05:43AM  Agios Pharmaceuticals (AGIO) Up 13.4% Since Earnings Report: Can It Continue? Zacks
Jun-02-18 04:05PM  Updated Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1m Relapsed or Refractory AML Continue to Show Durable Responses as a Single Agent GlobeNewswire
Jun-01-18 04:15PM  Agios Presents Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma and Other Solid Tumors GlobeNewswire
08:30AM  Today's Research Reports on Trending Tickers: Tesaro and Agios Pharmaceuticals ACCESSWIRE
08:16AM  Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO Benzinga
May-31-18 04:04PM  Investors Should Own Agios For 'The Next Several Years,' Analyst Says Benzinga
May-30-18 03:17PM  Agios Pharmaceuticals Has Emerged From a 2-Year Base Pattern TheStreet.com
May-24-18 04:18PM  Agios (AGIO) Progressing Well on Pipeline Amid Competition Zacks
May-17-18 07:50AM  Market Trends Toward New Normal in Agios Pharmaceuticals, Corcept Therapeutics, Prestige Brand, Virtu Financial, Eagle Pharmaceuticals, and Century Aluminum Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
May-16-18 05:02PM  Agios to Present New Clinical Data from its IDH Programs at ASCO GlobeNewswire
May-07-18 03:28PM  Agios (AGIO) Q1 Loss Wider than Expected, Revenues Miss Zacks
May-04-18 07:42AM  Agios (AGIO) Q1 Loss Wider than Expected; Sales Miss Zacks
07:09AM  Agios Pharmaceuticals: 1Q Earnings Snapshot Associated Press
07:00AM  Agios Provides Business Update on Discovery Research Strategy and Pipeline, Progress on Clinical Programs, Commercial Launch Preparations and Reports First Quarter 2018 Financial Results at Investor Day GlobeNewswire
Apr-30-18 11:37AM  Is a Beat in the Cards for Agios (AGIO) in Q1 Earnings? Zacks
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology for the treatment of cancer and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Biller ScottChief Scientific OfficerApr 05Option Exercise39.763,000119,28029,511Apr 09 04:59 PM
Biller ScottChief Scientific OfficerApr 05Sale67.713,000203,13526,511Apr 09 04:59 PM
Bowden ChristopherChief Medical OfficerApr 01Option Exercise35.1610,000351,60017,238Apr 03 04:12 PM
Bowden ChristopherChief Medical OfficerApr 01Sale66.5710,000665,7477,238Apr 03 04:12 PM
Bowden ChristopherChief Medical OfficerMar 15Option Exercise35.1610,000351,60017,238Mar 19 04:25 PM
Bowden ChristopherChief Medical OfficerMar 15Sale64.1610,000641,6157,238Mar 19 04:25 PM
Biller ScottChief Scientific OfficerMar 05Option Exercise38.603,000115,80529,511Mar 07 04:06 PM
Biller ScottChief Scientific OfficerMar 05Sale67.683,000203,03226,511Mar 07 04:06 PM
Hoerter Steven L.Chief Commercial OfficerMar 04Option Exercise39.765,000198,80015,941Mar 05 04:04 PM
Hoerter Steven L.Chief Commercial OfficerMar 04Sale68.005,000340,00010,941Mar 05 04:04 PM
Hoerter Steven L.Chief Commercial OfficerMar 01Option Exercise39.765,000198,80015,941Mar 05 04:04 PM
Hoerter Steven L.Chief Commercial OfficerMar 01Sale66.015,000330,05010,941Mar 05 04:04 PM
Biller ScottChief Scientific OfficerFeb 27Option Exercise15.109,000135,87535,511Mar 01 04:02 PM
Biller ScottChief Scientific OfficerFeb 27Sale65.009,000585,00026,511Mar 01 04:02 PM
Biller ScottChief Scientific OfficerDec 21Option Exercise2.3420,50047,91924,637Dec 26 04:39 PM
Biller ScottChief Scientific OfficerNov 05Option Exercise9.053,00027,15053,932Nov 07 04:09 PM
Biller ScottChief Scientific OfficerNov 05Sale69.693,000209,07150,932Nov 07 04:09 PM
Biller ScottChief Scientific OfficerOct 05Option Exercise9.053,00027,15053,932Oct 09 04:09 PM
Biller ScottChief Scientific OfficerOct 05Sale69.793,000209,37750,932Oct 09 04:09 PM
Alenson CarmanPrincipal Accounting OfficerSep 28Sale76.4515211,6200Feb 20 04:01 PM
MARAGANORE JOHNDirectorSep 12Sale71.7414,1621,015,98222,047Sep 13 04:01 PM
MARAGANORE JOHNDirectorSep 11Sale72.7513,555986,12936,209Sep 13 04:01 PM
Schenkein David PChief Executive OfficerSep 10Option Exercise31.648,730276,21783,849Sep 12 04:12 PM
Biller ScottChief Scientific OfficerSep 05Option Exercise9.053,00027,15060,196Sep 07 04:12 PM
Schenkein David PChief Executive OfficerSep 05Option Exercise3.3275,119249,02875,119Sep 07 04:22 PM
Alenson CarmanPrincipal Accounting OfficerSep 05Option Exercise52.2931216,314464Sep 07 04:18 PM
Biller ScottChief Scientific OfficerSep 05Sale83.073,000249,21557,196Sep 07 04:12 PM
Alenson CarmanPrincipal Accounting OfficerSep 05Sale83.0031225,896152Sep 07 04:18 PM
Bowden ChristopherChief Medical OfficerAug 30Option Exercise35.161,70059,7722,624Aug 31 04:02 PM
Bowden ChristopherChief Medical OfficerAug 30Sale80.031,700136,051924Aug 31 04:02 PM
Bowden ChristopherChief Medical OfficerAug 29Option Exercise35.1630010,5481,224Aug 31 04:02 PM
Bowden ChristopherChief Medical OfficerAug 29Sale80.0030024,000924Aug 31 04:02 PM
Hoerter Steven L.Chief Commercial OfficerAug 24Option Exercise39.762,05081,5082,050Aug 28 04:06 PM
Hoerter Steven L.Chief Commercial OfficerAug 24Sale74.922,050153,5860Aug 28 04:06 PM
Biller ScottChief Scientific OfficerAug 06Option Exercise9.053,00027,15060,196Aug 08 04:14 PM
Biller ScottChief Scientific OfficerAug 06Sale80.113,000240,33357,196Aug 08 04:14 PM
Hoerter Steven L.Chief Commercial OfficerJul 25Option Exercise39.762,05081,5082,050Jul 27 04:01 PM
Hoerter Steven L.Chief Commercial OfficerJul 25Sale84.582,050173,3890Jul 27 04:01 PM
Bowden ChristopherChief Medical OfficerJul 10Option Exercise35.162,00070,3202,924Jul 12 04:14 PM
Bowden ChristopherChief Medical OfficerJul 10Sale86.762,000173,512924Jul 12 04:14 PM
Alenson CarmanPrincipal Accounting OfficerJul 09Option Exercise52.2927214,223272Jul 11 04:23 PM
Alenson CarmanPrincipal Accounting OfficerJul 09Sale84.9427223,1040Jul 11 04:23 PM
Biller ScottChief Scientific OfficerJul 05Option Exercise9.053,00027,15060,196Jul 09 04:08 PM
Biller ScottChief Scientific OfficerJul 05Sale83.503,000250,50357,196Jul 09 04:08 PM
Hoerter Steven L.Chief Commercial OfficerJun 22Option Exercise39.762,05081,5082,050Jun 26 04:02 PM
Hoerter Steven L.Chief Commercial OfficerJun 22Sale97.582,050200,0390Jun 26 04:02 PM
Foster-Cheek Kaye IDirectorJun 14Option Exercise50.739,000456,57011,200Jun 18 04:05 PM
Foster-Cheek Kaye IDirectorJun 14Sale93.559,000841,9262,200Jun 18 04:05 PM
Bowden ChristopherChief Medical OfficerJun 12Option Exercise35.162,00070,3202,881Jun 14 04:23 PM
Bowden ChristopherChief Medical OfficerJun 12Sale92.892,000185,786881Jun 14 04:23 PM
Biller ScottChief Scientific OfficerJun 05Option Exercise9.053,00027,15060,196Jun 07 04:02 PM
Biller ScottChief Scientific OfficerJun 05Sale93.373,000280,10157,196Jun 07 04:02 PM
Schenkein David PChief Executive OfficerJun 01Option Exercise0.4813,0006,28013,000Jun 05 04:10 PM
Schenkein David PChief Executive OfficerJun 01Sale95.3513,0001,239,6080Jun 05 04:10 PM
Schenkein David PChief Executive OfficerMay 30Option Exercise0.3945,62617,67545,626Jun 01 04:08 PM
Schenkein David PChief Executive OfficerMay 30Sale90.0745,6264,109,5340Jun 01 04:08 PM
Biller ScottChief Scientific OfficerMay 23Option Exercise31.6415,177480,20072,373May 29 06:11 AM
Hoerter Steven L.Chief Commercial OfficerMay 23Option Exercise39.762,05081,5082,050May 29 06:14 AM
Schenkein David PChief Executive OfficerMay 23Option Exercise0.3049,37414,93649,374May 29 06:17 AM
Schenkein David PChief Executive OfficerMay 23Sale90.4049,3744,463,5240May 29 06:17 AM
Hoerter Steven L.Chief Commercial OfficerMay 23Sale85.762,050175,8080May 29 06:14 AM
Biller ScottChief Scientific OfficerMay 23Sale90.0015,1771,365,93057,196May 29 06:11 AM
Bowden ChristopherChief Medical OfficerMay 08Option Exercise35.162,00070,3202,881May 10 04:00 PM
Bowden ChristopherChief Medical OfficerMay 08Sale81.382,000162,760881May 10 04:00 PM
Biller ScottChief Scientific OfficerMay 07Option Exercise9.053,00027,15060,196May 08 04:08 PM
Biller ScottChief Scientific OfficerMay 07Sale81.813,000245,43057,196May 08 04:08 PM
Schenkein David PChief Executive OfficerMay 01Option Exercise0.3013,0003,93313,000May 03 04:07 PM
Schenkein David PChief Executive OfficerMay 01Sale83.0413,0001,079,5010May 03 04:07 PM